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We have reported that the selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib (‘Iressa’, ZD1839),
suppressed intrahepatic metastasis of hepatocellular carcinoma CBO140C12 cells. In this study, we focused on the tumour necrosis
factor-a (TNF-a) signalling pathways. Real-time reverse transcription–polymerase chain reaction showed that TNF-a mRNA was
expressed in large quantities in the implanted tumour. Gefitinib inhibited EGF- but not hepatocyte growth factor (HGF)-induced
activation of mitogen-activated protein kinase (MAPK) cascades, suggesting selectivity of the inhibitor. However, gefitinib inhibited the
TNF-a-induced activation of MAPKs and Akt. In addition, TNF-a-induced metastatic properties including adhesion to fibronectin,
mRNA expression of integrin av, production of matrix metalloproteinase-9 and invasion were inhibited by gefitinib without affecting
cell proliferation. Furthermore, the TNF-a-induced responses except for NF-kB activation were blocked by metalloprotease
inhibitors, suggesting that gefitinib inhibited the transactivation of EGFR induced by TNF-a. These results suggest that the TNF-a
signalling pathway is a possible target of gefitinib in suppressing the intrahepatic metastasis of hepatocellular carcinoma.
British Journal of Cancer (2005) 92, 1690–1695. doi:10.1038/sj.bjc.6602548 www.bjcancer.com
Published online 19 April 2005
& 2005 Cancer Research UK
Keywords: gefitinib; tumour necrosis factor alpha; epidermal growth factor; hepatocellular carcinoma; signalling pathways; metastases
                                             
High expression of epidermal growth factor receptor (EGFR)
has been observed in a variety of tumours, including the lung
and liver (Ito et al, 2001; Nicholson et al, 2001), which has been
shown to correlate with disease progression, poor survival,
poor response to therapy and the development of resistance to
cytotoxic agents (Arteaga, 2002; Ritter and Arteaga, 2003). Upon
ligand binding, EGFR dimerisation triggers protein kinase activity
of the intracellular tyrosine kinase domain (Baselga, 2002).
Gefitinib (‘Iressa’, ZD1839 (‘Iressa’ is a trademark of the
AstraZeneca group of companies)), an EGFR tyrosine kinase
inhibitor, exhibits a broad antitumour spectrum against
human cancers in vitro and demonstrated therapeutic benefit in
patients with non-small-cell lung cancer (Ciardiello et al, 2000;
Sirotnak et al, 2000; Herbst and Bunn, 2003). There is no
correlation between the antitumour activity of gefitinib and EGFR
expression level; however, recent research revealed that gefitinib-
responsive lung cancers harbour somatic mutations within the
EGFR kinase domain (Lynch et al, 2004; Paez et al, 2004; Sordella
et al, 2004).
Tumour necrosis factor-a (TNF-a) was first identified as the
macrophage-derived product responsible for tumouricidal activity
(Matthews, 1978; Matthews and Watkins, 1978; Pennica et al,
1985). However, extensive research during past years has made it
apparent that TNF-a enhances the incidence of metastasis in
several tumour models (Orosz et al, 1993; Qin et al, 1993; Kitakata
et al, 2002; Mochizuki et al, 2004; Tomita et al, 2004). The role of
endogenous TNF-a in the metastatic process remains to be
clarified; however, TNF-a has been found to increase the
expression of adhesion molecules and invasive molecules, includ-
ing intracellular adhesion molecule-1 (ICAM-1) and matrix
metalloproteinase-9 (MMP-9) (Aggarwal et al, 2002). In addition,
we have recently reported that stimulation of cultured colon 26
cells with TNF-a promotes lung metastasis through the extra-
cellular signal-regulated kinase (ERK) signalling pathway (Choo
et al, 2005).
Epidermal growth factor receptor transactivation by ligand-
independent intracellular signalling mechanisms and metallopro-
tease-mediated processing of the EGF-like ligands has been
investigated in the last couple of years (Fischer et al, 2003).
Recently, the transactivation of EGFR by TNF-a-induced metallo-
protease processing of TGF-a has been demonstrated in hepato-
cytes and mammary epithelial cells (Argast et al, 2004; Chen et al,
2004). These findings raise a possibility that TNF-a signalling
pathways are potential targets for the antitumour activity of
gefitinib.
Recently, we have shown that gefitinib is effective in inhibiting
intrahepatic metastasis of murine hepatocellular carcinoma
CBO140C12 cells by blocking EGFR-dependent metastatic proper-
ties (Matsuo et al, 2003). In this study, we found that gefitinib also
inhibited the TNF-a-induced activation of mitogen-activated
protein kinase (MAPK) cascades and Akt as well as TNF-a-
induced metastatic properties in vitro possibly by inhibiting EGFR
transactivation.
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Reagents
Gefitinib was kindly provided by AstraZeneca (Macclesfield, UK).
It was dissolved in DMSO for the in vitro study. Recombinant
murine EGF were purchased from Upstate Biotechnology and
murine hepatocyte growth factor (HGF) and human TNF-a were
purchased from Genzyme/Techne. Metalloprotease inhibitors,
GM6001, GM6001 negative and TAPI-1, were purchased from
Calbiochem, Darmstadt, Germany.
Intrahepatic metastasis model by orthotopic implantation
Female 5-week-old specific pathogen-free B6C3F1 mice were
purchased from Japan SLC (Hamamatsu, Japan). The mice were
maintained under specific pathogen-free conditions and used
according to institutional guidelines. Orthotopic implantation of
CBO140C12 tumour fragments into mouse liver was performed as
described previously (Sawada et al, 2001; Matsuo et al, 2003). The
mice were killed on day 14 and total RNA was prepared from the
liver and primary tumour mass, and then subjected to real-time
reverse transcription–polymerase chain reaction (RT–PCR) as
described below.
Reverse transcription–polymerase chain reaction
Total RNA from CBO140C12 cells was extracted using the RNeasy
Mini Kit (QIAGEN, Hilden, Germany). First strand cDNA was
prepared from the total RNA (1mg) using oligo(dT) primer and
SuperScript II reverse transcriptase (Invitrogen, Carlsbad, USA).
The cDNA was conducted in a 25ml final volume mixture containing
primer, probe and TaqMan Universal PCR Master Mix. Probes were
labelled with fluorescent reporter dye at the 50-end (glyceralde-
hydes-3-phosphate dehydrogenase (GAPDH): VIC; TNF-a:F A M ;
MMP-9: FAM) and a quencher dye at the 30-end (GAPDH: TAMRA;
TNF-a: MGB; MMP-9: MGB). Plates were analysed on a TaqMan
ABI Prism 7700 Sequence Detector (Applied Biosystems, Carlsbad,
USA). Cycling parameters were: 501Cf o r2m i n ,9 5 1C for 10min, 40
cycles for GAPDH and TNF-a,5 0c y c l e sf o rM M P - 9a t9 5 1C for 15s
and 601C for 1min. Cycle threshold detection was converted into
number of cDNA contents in the starting material and a standard
curve was constructed using the known amounts of cDNA. Test
gene mRNA values were extrapolated from the standard curve and
expressed in arbitrary units.
Amplification of integrin av subunit mRNA was performed by
standard RT–PCR using specific oligonucleotide primers and an EX
Taq PCR kit (Takara-bio Co., Ltd., Shiga, Japan). The sequences of
the primers were as follows: integrin av, 50-CAAGCTCACTCCCAT
CAC-30 and 50-GGGTGTCTTGATTCTCAAAGGG-30; GAPDH,
50-GGTGAAGGTCGGTGTGAACGGATTT-30 and 50-GATGCCAAA
GTTGTCATGGATGACC-30. Polymerase chain reaction was pre-
formed in a thermocycler for specified cycles of denaturation (941C,
30s), annealing (601C, 60s) and extension (721C, 90s). The PCR
products were electrophoresed on 1.2% agarose gels and detected by
ethidium bromide staining.
Cell culture
The CBO140C12 murine hepatocellular carcinoma cell line was
kindly provided by Dr K Ogawa (Asahikawa Medical College,
Japan) and maintained in DMEM:F-12 supplemented with 10%
FCS, 320mgl
 1 L-glutamine. A549 cells were maintained in DMEM
supplemented with 10% FCS.
Cell proliferation assay
Cells (1 10
4cellswell
 1) were seeded in 100ml of medium
containing 0.5%. FCS in 96-well plates and allowed to adhere for
24h. After preincubation with 90ml of medium containing gefitinib
(final concentration 1mM) for 15min, cells were stimulated with
10ml of medium containing TNF-a (final concentration 10ngml
 1)
for 12 or 72h. Cell proliferation was determined by using a cell
counting kit (Dojindo).
Western blot analysis
Cells were cultured in a medium containing 0.5% FBS for 24h.
After indicated treatment, cell lysates were prepared with sample
buffer (25mM Tris-HCl (pH 6.8), 5% wv
 1 glycerol, 1% wv
 1 SDS,
0.05% wv
 1 bromophenol blue) and were subjected to sodium
dodecyl sulphate–polyacrylamide gel electrophoresis (SDS–
PAGE) and transferred to Immobilon-P membranes (Millipore).
Blots were probed using primary antibodies described above and
horseradish peroxidase-conjugated secondary antibodies (DAKO,
Glostrup, Denmark) followed by enhanced chemiluminescence
(Amersham, Piscatway, USA). Antibodies against EGFR and
phospho-EGFR, phospho-ERK, phospho-c-Jun-N-terminal kinase
(JNK), phospho-Akt, phospho-p38 and phospho-p65 were pur-
chased from Cell Signaling Technology, Beverly, USA and anti-p38,
JNK, p65 and Akt antibodies were obtained from Santa Cruz
Biotechnology, California, USA.
Adhesion assay
Cells in 0.1% BSA medium were pretreated with gefitinib for
15min and then stimulated with TNF-a for 12h. In all, 2 10
4 cells
were seeded on to the 96-well plate precoated with 1mgo f
fibronectin. After incubation for 25min, attached cells were
stained with 0.5% crystal violet. The cells were lysed with 30%
acetic acid, and the absorbance was measured at 590nm.
Invasion assay
The invasion assay was performed using Transwell culture chambers
(Corning Costar). Polyvinylpyrrolidone-free polycarbonate filters
with an 8.0mm pore size (Neuclepore) were precoated with 1mgo f
fibronectin on the lower surface, and then 5mg of Matrigel was
applied to the upper surface of the filter. Cells in 0.1% BSA medium
were pretreated with gefitinib for 15min, and then stimulated with
TNF-a for 12h. In all, 3 10
4 cells were added to the upper
compartment of the chamber and incubated for 6h at 371C. The cells
were stained with haematoxylin and eosin and were counted using
the mean of five windows ( 400 magnification) per filter.
Gelatin zymography
Gelatin zymography was performed as previously described
(Matsuo et al, 2003) with some modifications. Briefly, the
conditioned media was concentrated using Centricon (Millipore)
according to the manufacturer’s instructions and applied to 7.5%
SDS–polyacrylamide gels copolymerised with gelatine (0.1%
wv
 1) and incubated at 371C for 24h. Enzyme-digested regions
were quantified by the Chemi Doc XRS system (Bio-Rad).
Statistical analysis
The significance of differences between groups was determined by
applying Student’s two-tailed t-test.
RESULTS
Enhanced expression of TNF-a mRNA in tumour-
implanted liver
We have previously reported that gefitinib inhibits the sponta-
neous intrahepatic metastasis of hepatocellular carcinoma by
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2003). Here, we focused on the TNF-a signalling pathway. It has
been demonstrated that inflammatory cytokines including TNF-a
play critical roles in tumour metastasis. Therefore, we first tried to
detect mRNA expression of TNF-a in the intrahepatic metastasis
model using real-time RT–PCR (Figure 1). High-level expression
could be detected in the primary tumour mass. In contrast, mRNA
expression of TNF-a in the liver around the tumour was
comparable with normal and sham-operating liver. These results
confirm tumour-induced inflammatory reactions in the implanted
primary tumour.
Effects of gefitinib on EGF-, HGF- and TNF-a-induced
signalling pathways
Gefitinib is known as a selective EGFR tyrosine kinase inhibitor.
In fact, gefitinib inhibited EGF-induced EGFR autophosphoryla-
tion (Tyr-1068) as well as the downstream signalling pathways
including Akt, ERK, JNK and p38 MAPK in CBO140C12
cells (Figure 2). In contrast, HGF-induced activation of these
kinases was not affected by gefitinib (Figure 2). The selectivity of
the signalling pathways was correlated with our previous results,
which showed that gefitinib inhibited EGF- but not HGF-induced
chemotactic migration of CBO140C12 cells (Matsuo et al, 2003).
The signalling molecules tested above are also involved in the
TNF-a signalling, therefore, we next examined the effects of
gefitinib on the TNF-a-induced responses. Interestingly, TNF-a-
induced activation of MAPKs was significantly inhibited by
gefitinib in CBO140C12 cells (Figure 3A). Phosphorylation of Akt
was not affected by TNF-a and gefitinib (data not shown). It
should be noted that the inhibition was more potent compared
with the inhibitory activity against EGF-induced MAPK activation.
Gefitinib completely inhibited TNF-a-induced activation of ERK
and JNK at 0.1mM (Figure 3A); however, only a slight inhibition
was observed in EGF-induced MAPK activation at the same
concentration (Figure 2). In addition, activation of MAPK and Akt
was impaired in the presence of gefitinib in human cancer cell
lines, A549 (Figure 3B). In contrast, TNF-a-induced phosphoryla-
tion of NF-kB p65 subunit at Ser-536, an essential event for
activation of NF-kB (Sakurai et al, 1999), was not affected by
gefitinib in these cell lines (Figure 3A and B), indicating that
gefitinib did not block the TNF-a responses at the receptor level.
Effects of gefitinib on TNF-a-induced metastatic properties
It has been reported that TNF-a induces hepatocyte proliferation
(Argast et al, 2004). We examined the effect of TNF-a on the
growth of CBO140C12 cells. Stimulation with TNF-a for 72h
slightly increased cell proliferation (Figure 4B). We have
previously reported that gefitinib inhibits cell proliferation along
with caspase-3 activation in CBO140C12 cells (Matsuo et al, 2003).
The apoptotic activity of gefitinib was also detected even in the
presence of TNF-a (Figure 4B). However, neither gefitinib nor
TNF-a affected the growth during a 12-h incubation period
(Figure 4A).
Adhesion to the extracellular matrix and invasion across the
matrix and basement membrane are the critical steps in tumour
metastasis. CBO140C12 cells were stimulated with TNF-a for 12h
prior to the adhesion assay. TNF-a stimulated cell adhesion to
fibronectin and the increased adhesion was blocked by gefitinib
(Figure 5A). This is correlated with the inhibition of TNF-a-
induced mRNA expression of integrin av subunit, a counterpart
of fibronectin, by gefitinib (Figure 5B). In addition, gefitinib
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Figure 1 mRNA expression of TNF-a in the liver and tumour tissues
from the B6C3F1 mouse. B6C3F1 mice were given implantation with a
tumour fragment of CB140C12 cells, sham operation. Normal mice were
given no operation. Total RNAs were prepared from primary tumors, liver
tissues around the tumour, the sites of sham operation and normal livers,
and real-time RT–PCR was performed for quantification of relative mRNA
expression of TNF-a and GAPDH. All data are represented as mean7s.d.
of three mice.
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Figure 2 Selective inhibition of EGF-induced signalling pathways by
gefitinib in CBO140C12 cells. Serum-starved CBO140C12 cells were
pretreated for 15min with the indicated concentrations (mM) of gefitinib,
followed by the stimulation with 10ngml
 1 EGF, or 10ngml
 1 HGF for
5min. Phospho-EGFR, phospho-Akt, phospho-ERK, phospho-JNK and
phospho-p38 were determined by Western blotting using phospho-EGFR
(Tyr1068), phospho-Akt (Ser473), phospho-ERK (Thr202, Tyr204),
phospho-JNK (Thr183, Tyr185) and phospho-p38 (Thr180, Tyr182)
antibodies, respectively.
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the gelatinase activity (Figure 5D) of MMP-9 as well as TNF-a-
induced invasion of CBO140C12 cells (Figure 5C).
Effects of metalloprotease inhibitors on TNF-a-induced
cellular responces
To elucidate the possibility that responses to TNF-a in CBO140C12
cells are mediated by EGFR transactivaton, effects of metallopro-
tease inhibitors were examined. GM6001, a broad metalloprotease
inhibitor, blocked TNF-a-induced phosphorylation of ERK1/2
(Figure 6A). Activation of JNK and p38 was also inhibited by
GM6001 (data not shown), whereas phosphorylation of NF-kB p65
at Ser-536 was not inhibited (Figure 6A). In contrast, NegGM, a
structurally similar compound without metalloprotease inhibitory
activity, did not inhibit TNF-a-induced phosphorylation of ERK1/2
as well as phosphorylation of NF-kB (Figure 6A). It has recently
been demonstrated that shedding of EGFR ligands is mediated by
some members of the ADAMs family of metalloproteases,
especially ADAM17 (Hinkle et al, 2004; Sahin et al, 2004). We
therefore examined the effect of TAPI-1, an ADAMs inihibitor.
TNF-a-induced phosphorylation of ERK1/2 was inhibited by TAPI-
1 (Figure 6B). Both GM6001 and TAPI-1 did not inhibit EGF- and
HGF-induced phosphorylation of ERK1/2 (Figure 6C and data not
shown), indicating that these inhibitors selectively blocked the
TNF-a-induced signalling pathways. Moreover, TNF-a-induced
metastatic properties including the cell adhesion to fibronectin
(Figure 6D) and mRNA expression of integrin av (Figure 6E) were
inhibited by GM6001. The selective inhibiton by metalloprotease
inhibitors was similar to the inhibitory effects of gefitinib on the
TNF-a-induced cellular responces.
DISCUSSION
Epidermal growth factor receptor is a promising target for cancer
therapy and a number of anti-EGFR agents have been developed
(Blackledge and Averbuch, 2004). Preclinical investigations and
clinical studies of gefitinib have shown the benefits of anti-EGFR
therapy (Herbst and Bunn, 2003). It has recently been demon-
strated that TNF-a induces EGFR transactivation via metallopro-
teinase-dependent release of EGFR ligands. Therefore, we have
tired to examine the effects of gefitinib on the TNF-a-induced
cellular responces.
There has been accumulating evidence that inflammatory
mediators such as TNF-a promote malignant cell growth and
metastatic potential (Kitakata et al, 2002; Lozano et al, 2003).
Tumour metastasis is a complex process involving the release of
tumour cells from a primary tumour, entering of the vascular or
lymphatic circulation and extravasation to specific sites distant
from original tumour. These processes require tumour cell
attachment, migration, and invasion. In several tumour cell lines,
TNF-a induced the expression of several different adhesive
molecules including several integrin subunits, ICAM-1 and
VCAM-1 (Orosz et al, 1993; Qin et al, 1993; Choo et al, 2005).
Tumour necrosis factor-a also induced the activation of MAPKs,
which has been shown to be involved in MMP-9 expression and
invasion. In this study, we found that gefitinib inhibited not only
EGF-induced but also TNF-a-induced activation of MAPKs and
metastatic properties including adhesion and invasion. In addi-
tion, we have previously demonstrated that gefitinib inhibited
intrahepatic metastasis of CBO140C12 cells (Matsuo et al, 2003).
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Figure 3 Inhibition of TNF-a-induced MAPK activation by gefitinib in (A)
CBO140C12 and (B) A549 cells. Cells were treated with the indicated
concentrations (mM) of gefitinib for 15min, followed by the stimulation with
10ngml
 1 TNF-a for 10min. Phospho-ERK, phospho-JNK, phospho-p38,
phospho-Akt and phosphor-NF-kB p65 (Ser-536) were determined by
Western blotting.
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Figure 4 Effects of gefitinib and TNF-a on cell proliferation.
CBO140C12 cells were incubated with 1mM gefitinib and/or TNF-a for
12h (A)o r7 2 h( B), and cell proliferation was determined by WST-1
assay. *Po0.05, **Po0.01.
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sAbundant expression of TNF-a mRNA in primary tumour of
orthotopically implanted CBO140C12 cells in the liver support the
idea that TNF-a-meidated cellular activities are potential targets
for the antimetastatic activity of gefitinib. Moreover, TNF-a is one
of the angiogenic factors associated with tumour-induced neovas-
cularisation (Wu et al, 2000) and gefitinib has been shown to
inhibit EGFR-mediated migration and tube-like formation of
human microvascular endothelial cells (Hirata et al, 2002). These
results suggest that gefitinib affected TNF-a signalling pathways in
both tumour and endothelial cells. In our previous observation,
gefitinib inhibited the incidence of metastasis as well as the growth
of primary tumour (Matsuo et al, 2003). Therefore, antiangiogenic
activity by blocking the EGF- and TNF-a-induced reactions may be
one way gefitinib exerts its antitumour activity.
Recently, TNF-a and EGF signalling pathways have been found
to play a physiological function in TNF-a signalling (Hirota et al,
2001). It has been suggested that proteolytic release of transform-
ing growth factor-a, one of the EGFR ligands, is one possible
mechanism of EGFR transactivation by TNF-a (Argast et al, 2004;
Chen et al, 2004). Argast et al proved that MMPs, especially
ADAM17, is responsible for the transactivation of EGFR by TNF-a.
Here we confirmed that an ADAMs inhibitor TAPI-1 inhibited the
activation of TNF-a-induced MAPK activation. In addition, TNF-
a-induced metastatic properties in vitro such as adhesion were also
inhibited by a broad MMP inhibitor GM6001. These results
demonstrated that TNF-a-induced metastatic properties were
mediated via MMP activities. The fact that gefitinib inhibited the
TNF-a-induced cellular responses suggested the TNF-a-induced
EGFR transactivation by shedding EGFR ligands. Identification of
the ligands and MMPs will provide more information for the
mechanism of anti-TNF-a activity of gefitinib.
Tumour necrosis factor-a triggers several intracellular signalling
pathways, in which MAPK cascades and NF-kB are the main
pathways. In contrast to MAPK cascades, phosphorylation of NF-
kB p65 was not inhibited by both gefitinib and MMP inhibitors.
This is correlated with the finding that AG1478, an EGFR inhibitor,
did not inhibit TNF-a-induced phosphorylation of IkBa, another
event essential for activation of NF-kB, in hepatocytes (Argast
et al, 2004). In addition, it has been reported that TNF-a-induced
expression of chemokine RANTES, one of the NF-kB target genes,
was not blocked by the EGFR-neutralizing monoclonal antibody
225 in mammary epithelial cells (Chen et al, 2004). Collectively,
our observations support the proposed model that TNF-a-induced
NF-kB activation is independent of EGFR (Argast et al, 2004; Chen
et al, 2004).
In summary, we have demonstrated that gefitinib shows
antimetastatic activity using an intrahepatic metastasis model, in
which TNF-a-induced EGFR signalling are the possible targets.
Recent genome-wide approaches identified genes that may be
associated with sensitivity to gefitinib (Zembutsu et al, 2003; Lynch
et al, 2004; Paez et al, 2004). The accumulating evidence of
biochemical and genetic characterisation for the mechanism of
action will provide more information for the effective clinical use
of gefitinib.
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Figure 5 Effects of gefitinib on TNF-a-induced metastatic properties.
Cells were pretreated with 1mM gefitinib for 15min, followed by
stimulation with 10ngml
 1 TNF-a.( A) After a 12-h incubation, cells were
harvested and incubated in the wells precoated with fibronectin for 25min.
The adhesive cells were stained with crystal violet and absorbance was
meseaured. (B) After incubation for 6h, mRNAs encoding integrin av and
GAPDH were amplified by RT–PCR and visualized with ethidium bromide
staining. (C) After a 12-h incubation, cells were harvested and seeded into
the invasion chamber precoated with 1mg fibronectin on the lower surface
and 5mg Matrigel on the upper surface of the filter. After a 6-h incubation,
chambers were stained with haematoxylin and eosin and the numbers of
cells invaded were counted under a  400 microscope. (D) After a 12-h
incubation, the conditioned medium was analysed using gelatin zymogra-
phy. The activities were quantified by the Chemi-Doc XRS system.
*Po0.05, **Po0.01.
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Figure 6 Effects of MMP inhibitors on TNF-a-induced MAPK activation
and adhesion. Cells were pretreated with the indicated concentrations (mM)
of GM6001, GM6001 negative (NegGM) or TAPI-1 for 30min, followed by
stimulation with TNF-a (A, B) for 10min, or EGF for 5min (C). Phospho-
ERK and phosphor-NF-kB p65 were determined by Western blotting. (D)
Cells treated with 10mM GM6001/NegGM and TNF-a for 12h were tested
in adhesion assay. (E) RT–PCR was performed using cells treated with
10mM GM6001/NegGM and TNF-a for 6h. *Po0.01.
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